Literature DB >> 1899537

Tissue plasminogen activator treatment of experimental subretinal hemorrhage.

H Lewis1, S C Resnick, J G Flannery, B R Straatsma.   

Abstract

To determine if tissue plasminogen activator, a clot-specific fibrinolytic agent, could eventually be used to assist in the clearance or removal of subretinal hemorrhage, we studied the effect of subretinal injections of tissue plasminogen activator, autologous blood, balanced salt solution, and the combination of either tissue plasminogen activator or balanced salt solution after subretinal injection of autologous blood on retinal morphologic characteristics and clearance of subretinal hemorrhage in the albino rabbit. No morphologic evidence of tissue plasminogen activator toxicity was found in the rabbit retina at a dose of 25 to 50 micrograms/0.1 ml. Subretinal hemorrhage cleared faster after subretinal injection of tissue plasminogen activator when compared to balanced salt solution (P = .0005) but did not completely prevent overlying retinal degeneration. Both tissue plasminogen activator and balanced salt solution were found to decrease the toxic effects of subretinal blood on the morphologic characteristics of the rabbit retina, and this effect can be explained at least partly by dilution of the subretinal blood.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899537     DOI: 10.1016/s0002-9394(14)72259-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  21 in total

1.  Decreased choriocapillaris perfusion following surgical excision of choroidal neovascular membranes in age-related macular degeneration.

Authors:  M A Nasir; I Sugino; M A Zarbin
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

2.  Plasminogen in proliferative vitreoretinal disorders.

Authors:  P Esser; K Heimann; K U Bartz-Schmidt; P Walter; R Krott; M Weller
Journal:  Br J Ophthalmol       Date:  1997-07       Impact factor: 4.638

3.  Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator: a modified procedure to drain massive subretinal haemorrhage.

Authors:  Y Oshima; M Ohji; Y Tano
Journal:  Br J Ophthalmol       Date:  2006-08-17       Impact factor: 4.638

4.  Plasminogen activators promote excitotoxicity-induced retinal damage.

Authors:  Raghuveer S Mali; Mei Cheng; Shravan K Chintala
Journal:  FASEB J       Date:  2005-08       Impact factor: 5.191

5.  The use of tissue plasminogen activator in post-traumatic total hyphaema.

Authors:  L Laatikainen; J Mattila
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-01       Impact factor: 3.117

6.  The use of tissue plasminogen activator in postvitrectomy cases.

Authors:  C Koutsandrea; M Apostolopoulos; P Theodossiadis
Journal:  Int Ophthalmol       Date:  1993-04       Impact factor: 2.031

7.  Early-onset macular holes following ruptured retinal arterial macroaneurysms.

Authors:  Rina Sato; Tsutomu Yasukawa; Yoshio Hirano; Yuichiro Ogura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-03       Impact factor: 3.117

8.  Management of subretinal macular haemorrhage by direct administration of tissue plasminogen activator.

Authors:  R P Singh; C Patel; J E Sears
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

9.  Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration?

Authors:  R Machemer; U H Steinhorst
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-11       Impact factor: 3.117

10.  Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema.

Authors:  W Andrew Mould; J Ricardo Carhuapoma; John Muschelli; Karen Lane; Timothy C Morgan; Nichol A McBee; Amanda J Bistran-Hall; Natalie L Ullman; Paul Vespa; Neil A Martin; Issam Awad; Mario Zuccarello; Daniel F Hanley
Journal:  Stroke       Date:  2013-02-07       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.